[February 03, 2014] |
|
Enanta Pharmaceuticals Announces the Appointment of Timothy D. Ocain, Ph.D. as Senior Vice President, New Product Strategy and Development
WATERTOWN, Mass. --(Business Wire)--
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the
appointment of Timothy D. Ocain, Ph.D. as Senior Vice President, New
Product Strategy and Development. Dr. Ocain has over 25 years'
experience working in the pharmaceutical and biotechnology environment
with experience in medicinal chemistry, pharmacology, biochemistry,
program management and preclinical and early development across multiple
therapeutic areas. He is co-author on over 30 publications and
co-inventor on 17 patents.
"As Enanta begins to advance its internal candidates and seeks new
development areas, Tim's broad experience in drug discovery and business
development will be an invaluable resource to the company," stated Jay
R. Luly, Ph.D. President and Chief Executive Officer.
Dr. Ocain has held senior management and executive positions across a
wide range of small, mid and large cap biotechnology and pharmaceutical
companies. Since 2010, Dr. Ocain has been an independent biotechnology
consultant providing conulting services to a variety of companies. From
2006-2009, he was a member of the executive team as the Senior Vice
President, Research and Development at Seaside Therapeutics, a company
focused on neurodevelopmental disorders. Previously, he worked at
Millennium Pharmaceuticals from 1998-2006 and held positions of
increasing responsibility in drug discovery, program management and
mostly recently held the position of Vice President, Inflammation
Discovery. From 1993-1998 he worked at Procept, Inc, where he held
senior level drug discovery positions, with additional responsibility
for business development activities. Prior to Procept, he served in the
medicinal chemistry department at Wyeth-Ayerst Research from 1986-1993.
Dr. Ocain received his B.S. in Biological Sciences from the University
of Wisconsin-Eau Claire and his Ph.D. in Pharmaceutical Chemistry from
the University of Wisconsin-Madison, and completed his post-Doctoral
Fellowship in Chemistry at the University of Minnesota.
About Enanta
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven approach and
drug discovery capabilities to create small molecule drugs in the
infectious disease field. Enanta is discovering, and in some cases
developing, novel inhibitors designed for use against the hepatitis C
virus (HCV). These inhibitors include members of the direct acting
antiviral (DAA) inhibitor classes - protease (partnered with AbbVie),
NS5A (partnered with Novartis) and nucleotide polymerase - as well as a
host-targeted antiviral (HTA) inhibitor class targeted against
cyclophilin. Additionally, Enanta has created a new class of
antibiotics, called Bicyclolides, for the treatment of multi-drug
resistant bacteria, with a focus on developing an intravenous and oral
treatment for hospital and community MRSA (methicillin-resistant Staphylococcus
aureus) infections.
[ Back To TMCnet.com's Homepage ]
|